Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Non-GAAP Adjusted Diluted EPS by Year
Non-GAAP Adjusted Diluted EPS ($/share) ($)
Pfizer Non-GAAP Adjusted Diluted EPS: $3.22 in FY2025, up 3.5% from a year earlier.
Latest, FY2025
3.22
Period ended Dec 31, 2025
Change on a year earlier
+3.5%
3.11 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Where the FY2025 figure comes from
“|| Adjusted (3) Diluted EPS | 0.66 | 0.63 | 5% | 3.22 | 3.11 | 4%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Non-GAAP Reconciliation Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Non-GAAP Adjusted Diluted EPS ($), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/adj-diluted-eps
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.